

Contents

List of principal contributors	ix
Foreword	xxi
Section I: The New Helicobacters	
1 What are the new helicobacters? <i>A Lee and JL O'Rourke</i>	3
2 <i>Helicobacter hepaticus</i> and <i>Helicobacter bilis</i> : proinflammatory modulators of enterohepatic disease <i>JG Fox</i>	15
3 Epidemiology and postulated pathogenesis of liver and biliary tract pathogenic <i>Helicobacter</i> species <i>T Wadström, SO Hynes and Å Ljungh</i>	31
4 Evidence implicating <i>Helicobacter</i> spp. in the pathogenesis of inflammatory bowel disease <i>C Streutker and K Croitoru</i>	43
Section II: Strain Differences of <i>Helicobacter pylori</i>	
5 The hierarchy of markers of virulence and disease causation – useful or disappointing? <i>JG Kusters and AHM van Vliet</i>	55
6 SHP-2 tyrosine phosphatase and the <i>Helicobacter pylori</i> virulence factor CagA <i>M Asaka and M Hatakeyama</i>	65
7 What is the exact role of Lewis antigens and autoantibodies in <i>Helicobacter pylori</i> -related disease? <i>PB Ernst, K Ryan and JB Goldberg</i>	73
8 Putative role of <i>Helicobacter</i> antigen in functional dyspepsia: a conceptual model <i>P Bercik and S Collins</i>	83

CONTENTS

- 9** Acid adaptation of *Helicobacter pylori*
DR Scott, EA Marcus, DL Weeks, G Sachs 89
- 10** Co-migration of *Helicobacter pylori* and humans:
the evolving story
Y Yamaoka and DY Graham 101

Section III: *Helicobacter pylori* and Gastritis – The Ongoing Saga

- 11** Progress in our understanding of *H. pylori* infection and
gastritis
M Stolte, A Meining, S Miehlke and E Bayerdörffer 115
- 12** The role of pepsinogen assays as surrogate markers of
gastritis dynamics in population studies
P Sipponen, O Suovaniemi and M Härkönen 127
- 13** Multifocal Atrophic Gastritis (MAG) does not exist: new
finding based on sectioning the entire stomach
H El-Zimaity 133
- 14** Multifocal Atrophic Gastritis (MAG) is real, and important
P Correa 143
- 15** Are there reliable non-invasive approaches to assessing
gastritis for epidemiologic studies?
C-J Tsai and J Parsonnet 149
- 16** Animal models of gastritis: *Helicobacter pylori* and high-salt
diet in the gerbil
IT Padol, M Sager and RH Hunt 161

Section IV: *Helicobacter pylori* and Gastric Malignancy

- 17** The evolving epidemiology of *Helicobacter pylori* infection
and gastric cancer
J-Q Huang and RH Hunt 171
- 18** Virulence of *Helicobacter pylori* infection and gastric cancer:
lessons from mouse models
TC Wang, JG Fox and J-M Houghton 177
- 19** The role of bacterial overgrowth in the stomach as an
additional risk factor for gastritis
G Naylor and A Axon 185
- 20** Role of ascorbate in gastric juice and the impact of
Helicobacter pylori infection
MJG Farthing, G Smith and Z-W Zhang 195

CONTENTS

21	Mechanisms of injury: the effects of <i>Helicobacter pylori</i> on cell cycle control <i>SF Moss</i>	205
22	Role of interleukin-1 beta and other potential genetic markers as indicators of gastric cancer risk <i>E Troost, GL Hold, M Smith, W-H Chow, CS Rabkin, KEL McColl and EM El-Omar</i>	215
23	Results of intervention trials in <i>Helicobacter pylori</i> -infected populations <i>D Forman</i>	225
24	Which lessons can be drawn from the study of <i>Helicobacter pylori</i> related MALT lymphoma? <i>AC Wotherspoon</i>	231
 Section V: <i>Helicobacter pylori</i> and Clinical Issues		
25	<i>Helicobacter pylori</i> eradication leads to gastro-oesophageal reflux disease <i>J Labenz</i>	243
26	<i>Helicobacter pylori</i> eradication does not lead to gastro-oesophageal reflux disease <i>J Dent</i>	253
27	<i>Helicobacter pylori</i> eradication in non-ulcer dyspepsia: the case for <i>P Moayyedi</i>	265
28	<i>Helicobacter pylori</i> eradication does not benefit non-ulcer dyspepsia <i>L Laine</i>	275
29	<i>Helicobacter pylori</i> and dyspepsia strategies – debate: Yes – A test-and-treat strategy is a viable option in primary care <i>WA de Boer</i>	283
30	A ‘test-and-treat’ strategy is obsolete in primary care <i>CW Howden</i>	297
31	<i>Helicobacter pylori</i> should be eradicated in patients receiving long-term acid suppression <i>EJ Kuipers</i>	301
32	<i>Helicobacter pylori</i> eradication is not necessary before long-term proton pump inhibitor treatment <i>JW Freston</i>	311

CONTENTS

33	<i>Helicobacter pylori</i> and non-steroidal anti-inflammatory drugs: the debate is over <i>JJY Sung</i>	319
Section VI: Ongoing Clinical Issues with <i>Helicobacter pylori</i> Infection		
34	What are the global response rates to <i>Helicobacter pylori</i> eradication therapy? <i>C Nash, L Fischbach and S Veldhuyzen van Zanten</i>	329
35	What is the <i>Helicobacter pylori</i> global reinfection rate? <i>J Parsonnet</i>	339
36	Is it time for quadruple therapy to be first line? <i>L Laine</i>	347
37	Eradication therapy should be different for dyspeptic patients compared with ulcer patients <i>WA de Boer</i>	353
38	<i>Helicobacter pylori</i> resistance to antibiotics: prevalence, mechanism, detection. What's new? <i>F Mégraud</i>	363
39	Antibiotic sensitivities of <i>Helicobacter pylori</i> vary at different gastric mucosal sites <i>TJ Borody, R Clancy, EF Warren, R Surace, S Brusentsev and H Mitchell</i>	373
40	Can the response to eradication therapy in <i>Helicobacter pylori</i> infection be predicted? <i>R Clancy, T Borody, Z Ren and G Pang</i>	383
41	What constitutes failure of <i>H. pylori</i> eradication therapy? <i>P Malfertheiner, U Peitz and G Treiber</i>	391
42	How can the current strategies for eradication therapy be improved? <i>A Ford and P Moayyedi</i>	401
43	Novel targets for <i>Helicobacter pylori</i> eradication <i>G Sachs, Y Wen, D Weeks, EA Marcus and DR Scott</i>	413
44	<i>Helicobacter pylori</i> management: how to improve the therapeutic confusion in practice <i>NJ Talley</i>	423
45	Ethical issues in the management of <i>Helicobacter pylori</i> infection <i>A Axon</i>	433

CONTENTS

- 46** Are there geographic/regional differences in *Helicobacter pylori* eradication?
N Vakil 439

Section VII: Global Consensus Update

- 47** Management of *Helicobacter pylori* infection – a review of the available regional and national guidelines
S Sebastian, HJ O'Connor, MJ Buckley and CA O'Morain 447
- 48** Asia Pacific guidelines for the management of *Helicobacter pylori* infection
NJ Talley 463
- 49** What is the impact of the regional guidelines? China
SD Xiao 471
- 50** *H. pylori* infection: Clinical management from a European perspective
P Malfertheiner 475
- 51** What is the impact of the regional guidelines? South America
L Paula-Castro and LG Vaz Coelho 481
- 52** Guidelines for management of *Helicobacter pylori* infection in the Middle East
S Nayal 487
- 53** Global consensus update for managing *Helicobacter pylori* infection: critical issues from the United States
DA Peura 489
- 54** Guidelines in the management of *Helicobacter pylori* infection in Japan
M Asaka 497
- 55** A proposal for future *Helicobacter pylori* eradication guidelines
A Qasm, M Buckley, H O'Connor and C O'Morain 503

Section VIII: Priorities for Future Research

- 56** Priorities for future research: microbiology
A Lee, L Thompson and JL O'Rourke 515
- 57** Priorities for further research in *Helicobacter pylori* management – the way forward
A Axon 523
- Index 527